COCOA, Fla., June 9, 2011 /PRNewswire/ -- GeNO LLC (www.genollc.com), a privately held, advanced development-stage technology company, today announced it has been awarded a new patent for its NITROSYL (Inhaled Nitric Oxide) Systems. U.S. Patent No. 7,947,227, GeNO's seventh patent, concerns a method of providing a therapeutic amount of nitric oxide (NO) to a mammal in a manner that converts nitrogen dioxide (NO2) to nitric oxide (NO). The NO2 can originate from either a gas bottle or a liquid source. This new patent is set to expire in August 2029.
"It is unusual for a drug already in Phase II clinical trials to have the core technology protected by patents that still have at least 18 years of life," said GeNO LLC Founder and President David Fine. "This patent further solidifies the strong intellectual property foundation of the company and is an important milestone for the development of our novel NITROSYL Systems."
GeNO's NITROSYL Systems aim to add a valuable option for clinicians treating a range of serious pulmonary diseases with inhaled nitric oxide. GeNO's plans for both in-hospital and ambulatory inhaled nitric oxide systems would help address the cost, complexity and lack of portability of current treatment regimens, and would potentially reach a much larger group of patients.
Additional study details can be found on http://clinicaltrials.gov/ -- ClinicalTrials.gov Identifiers NCT01092559 and NCT01265888.
ABOUT GENO LLC
GeNO LLC, founded in 2006, is a privately held, advanced development-stage technology company that is developing innovative nitric oxide (NO) generation and delivery platforms to enable the true potential of inhaled nitric oxide to be realized. The company is focused on applying the new technology to deliver inhaled nitric oxide to patients in a wide variety of settings, including ambulatory and in-home use for potential chronic treatment. GeNO's NITROSYL Systems will be regulated by the FDA as new drugs with their own NDAs. These systems have been designated as Combination Products by the FDA Office of Combination Products, with the Division of Cardiovascular and Renal Products designated as the lead reviewer for GeNO's initial INDs. The company has seven US patents with numerous additional patent applications pending.
Carla Burigatto, 610-457-2178
Brian Heffron, 781-799-9568
SOURCE GeNO LLC